Dh166, a beta-carboline derivative, inhibits the kinase activity of PLK1

Cancer Biology and Therapy

Volumn 8, Issue 24, 2009, Pages 2374-2383

  Zhang, Jing ^a   Li, Yan ^a   Guo, Liang ^b   Cao, Rihui ^b   Zhao, Pei ^a   Jiang, Wei ^a   Ma, Qin ^b   Yi, Hong ^a   Li, Zhuorong ^a   Jiang, Jiandong ^a   Wu, Jialin ^b   Wang, Yanchang ^c   Si, Shuyi ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b Xinjiang Huashidan Pharmaceutical Co   (China)

^c FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Beta carboline; Cancer; Cdc5; DH166; Multi target drug; PLK1

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA CARBOLINE DERIVATIVE; CYCLIN B1; DH 166; PHOSPHOTRANSFERASE INHIBITOR; POLO LIKE KINASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DOWN REGULATION; DRUG BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; ENZYME STRUCTURE; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MITOSIS INHIBITION; MITOSIS SPINDLE; NONHUMAN; YEAST CELL;

EID: 75749138951     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.24.10182     Document Type: Article

References (45)

1. Donohue PJ, Alberts GF, Guo Y, Winkles JA. Identification by targeted differential display of an immediate early gene encoding a putative serine/threonine kinase. J Biol Chem 1995; 270:10351-7.
2. Liby K, Wu H, Ouyang B, Wu S, Chen J, Dai W. Identification of the human homologue of the early-growth response gene Snk, encoding a serum-inducible kinase. DNA Seq 2001; 11:527-33.
3. Simmons DL, Neel BG, Stevens R, Evett G, Erikson RL. Identification of an early-growth-response gene encoding a novel putative protein kinase. Mol Cell Biol 1992; 12:4164-9.
4. Fode C, Motro B, Yousefi S, Heffernan M, Dennis JW. Sak, a murine protein-serine/threonine kinase that is related to the drosophila polo kinase and involved in cell proliferation. Proc Natl Acad Sci 1994; 91:6388-92.
5. Kumagai A, Dunphy WG. Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 1996; 273:1377-80.
6. Llamazares S, Moreira A, Tavares A, Girdham C, Spruce BA, Gonzalez C, et al. Polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev 1991; 5:2153-65.
7. Tanaka K, Petersen J, MacIver F, Mulvihill DP, Glover DM, Hagan IM. The role of Plo1 kinase in mitotic commitment and septation in Schizosaccharomyces pombe. EMBO J 2001; 20:1259-70.
8. 1 cell cycle mutant gene dbf4 encodes a protein kinase and is identified as CDC5. Mol Cell Biol 1993; 13:4445-57.
9. Descombes P, Nigg EA. The polo-like kinase Plx1 is required for M phase exit and destruction of mitotic regulators in Xenopus egg extracts. EMBO J 1998; 17:1328-35.
10. Shirayama M, Zachariae R, Ciosk R, Nasmyth K. The Polo-like kinase Cdc5p and the WD-repeat protein Cdc20p/fizzy are regulators and substrates of the anaphase promoting complex in Saccharomyces cerevisiae. EMBO J 1998; 17:1336-49.
11. Sunkel CE, Glover DM. polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J Cell Sci 1988; 89:25-38.
12. Ma S, Liu MA, Yuan YL, Erikson RL. The serum-inducible protein kinase Snk is a G1 phase polo-like kinase that is inhibited by the calcium- and integrin-binding protein CIB. Mol Cancer Res 2003; 1:376-84.
13. Ouyang B, Pan H, Lu L, Li J, Stambrook P, Li B, et al. Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions. J Biol Chem 1997; 272:28646-51.
14. Wang Q, Xie S, Chen J, Fukasawa K, Naik U, Traganos F, et al. Cell cycle arrest and apoptosis induced by human Polo-like kinase 3 is mediated through perturbation of microtubule integrity. Mol Cell Biol 2002; 22:3450-9.
15. Xie S, Wu H, Wang Q, Cogswell JP, Husain I, Conn C, et al. Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J Biol Chem 2001; 276:43305-12.
16. Hudson JW, Kozarova A, Cheung P, Macmillan JC, Swallow CJ, Cross JC, et al. Late mitotic failure in mice lacking Sak, a polo-like kinase. Curr Biol 2001; 11:441-6.
17. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005; 24:287-91.
18. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321-30.
19. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005; 26:178-82.
20. Jiménez J, Riverón-Negrete L, Abdullaev F, Espinosa-Aguirre J, Rodríguez-Arnaiz R. Cytotoxicity of the beta-carboline alkaloids harmine and harmaline in human cell assays in vitro. Exp Toxicol Pathol 2008; 60:381-9.
21. Chen Q, Chao R, Chen H, Hou X, Yan H, Zhou S, et al. Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis. Int J Cancer 2005; 114:675-82.
22. Beljanski M, Beljanski MS. Selective inhibition of in vitro synthesis of cancer DNA by alkaloids of betacarboline class. Exp Cell Biol 1982; 50:79-87.
23. Sobhani AM, Ebrahimi SA, Mahmoudian M. An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids. J Pharm Pharm Sci 2002; 5:19-23.
24. Deveau AM, Labroli MA, Dieckhaus CM, Barthen MT, Smith KS, Macdonald TL. The synthesis of amino-acid functionalized betacarbolines as topoisomerase II inhibitors. Bioorg Med Chem Lett 2001; 11:1251-5.
25. Song Y, Wang J, Teng SF, Kesuma D, Deng Y, Duan J, et al. Beta-carbolines as specific inhibitors of cyclindependent kinases. Bioorg Med Chem Lett 2002; 12:1129-32.
26. Castro AC, Dang LC, Soucy F, Grenier L, Mazdiyasni H, Hottelet M, et al. Novel IKK inhibitors: betacarbolines. Bioorg Med Chem Lett 2003; 13:2419-22.
27. Hu F, Wang Y, Liu D, Li Y, Qin J, Elledge SJ. Regulation of the Bub2/Bfa1 GAP complex by Cdc5 and cell cycle checkpoints. Cell 2001; 107:655-65.
28. Liu H, Wang Y. The function and regulation of budding yeast Swe1 in response to interrupted DNA synthesis. Mol Biol Cell 2006; 17:2746-56.
29. Fu DH, Jiang W, Zheng JT, Zhao GY, Li Y, Yi H, et al. Jadomycin B, an Aurora-B kinase inhibitor discovered through virtual screening. Mol Cancer Ther 2008; 7:2386-93.
30. Liu X, Erikson RL. Polo-like kinase (Plk1) depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100:5789-94.
31. Eckerdt F, Strebhardt K. Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res 2006; 66:6895-8.
32. Kotani S, Tugendreich S, Fujii M, Jorgensen PM, Watanabe N, Hoog C, et al. PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex activity and mitosis progression. Mol Cell 1998; 1:371-80.
33. Zhou Qiong, Bai Ming, Jin Yang, Zhang Xiao-Ju, Yuan SU. Inhibition of Expression of Polo-like Kinase 1 by RNAi Interference in A549 Cells. Chin J of Biochem and Mol Biol 2005; 21:665-72.
34. Santamaria A, Neef R, Eberspächer U, Eis K, Husemann M, Mumberg D, et al. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell 2007; 18:4024-36.
35. Kothe M, Kohls D, Low S, Coli R, Cheng AC, Jacques SL, et al. Structure of the Catalytic Domain of Human Polo-like Kinase 1. Biochemistry 2007; 46:5960-71.
36. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008; 4:682-90.
37. Frantz S. Drug discovery: playing dirty. Nature 2005; 437:942-3.
38. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006; 5:993-6.
39. 3H]beta-carboline) to the ethanol-inducible cytochrome P450 2E1 in rat liver. Biochem Pharmacol 1999; 57:511-20.
40. Kim H, Sablin SO, Ramsay RR. Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch Biochem Biophys 1997; 337:137-42.
41. Li Y, Liang F, Jiang W, Yu F, Cao R, Ma Q, et al. DH334, a beta-carboline anti-cancer drug, inhibits the CDK activity of budding yeast. Cancer Biol Ther 2007; 6:1193-9.
42. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, et al. BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo. Curr Biol 2007; 17:316-22.
43. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, et al. Prognostic significance of polo-like kinase(PLK) expression in non-small cell lung cancer. Oncogene 1997; 14:543-9.
44. Zhou Q, Bai M, Su Y. Effect of antisense RNA targeting polo-like kinase 1 on cell cycle and proliferation in A549 cells. Chin Med J 2004; 117:1642-9.
45. Peters U, Cherian J, Kim JH, Kwok BH, Kapoor TM. Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat Chem Biol 2006; 2:618-26.